iRadimed (NASDAQ:IRMD) Releases Q1 2026 Earnings Guidance

iRadimed (NASDAQ:IRMD) issued an update on its first quarter 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.440-0.480 for the period, compared to the consensus earnings per share estimate of 0.440. The company issued revenue guidance of $21.0 million-$22.0 million, compared to the consensus revenue estimate of $20.8 million. iRadimed also updated its FY 2026 guidance to 2.060-2.210 EPS.

iRadimed Price Performance

Shares of NASDAQ IRMD opened at $95.97 on Tuesday. The stock has a market capitalization of $1.22 billion, a P/E ratio of 58.16 and a beta of 1.11. The stock’s 50 day moving average price is $97.82 and its two-hundred day moving average price is $83.09. iRadimed has a 52-week low of $47.48 and a 52-week high of $104.93.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. iRadimed had a return on equity of 22.93% and a net margin of 26.31%.The business had revenue of $22.69 million during the quarter, compared to the consensus estimate of $21.60 million. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. On average, analysts anticipate that iRadimed will post 1.66 EPS for the current year.

iRadimed Announces Dividend

The business also recently declared a special dividend, which was paid on Tuesday, December 30th. Investors of record on Wednesday, December 17th were issued a $0.50 dividend. The ex-dividend date of this dividend was Wednesday, December 17th. iRadimed’s dividend payout ratio (DPR) is 41.21%.

Analysts Set New Price Targets

IRMD has been the topic of a number of recent analyst reports. Zacks Research upgraded shares of iRadimed to a “hold” rating in a research note on Tuesday, November 4th. Wall Street Zen cut iRadimed from a “strong-buy” rating to a “buy” rating in a report on Sunday, October 26th. Weiss Ratings restated a “buy (b-)” rating on shares of iRadimed in a report on Monday, December 29th. Roth Mkm set a $90.00 target price on shares of iRadimed in a report on Friday, October 31st. Finally, Lake Street Capital restated a “buy” rating and set a $100.00 price target on shares of iRadimed in a report on Monday, November 3rd. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, iRadimed currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.00.

Insider Transactions at iRadimed

In other news, CFO John Glenn sold 15,000 shares of the stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $97.29, for a total transaction of $1,459,350.00. Following the transaction, the chief financial officer owned 7,362 shares of the company’s stock, valued at approximately $716,248.98. This represents a 67.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Roger E. Susi sold 5,000 shares of the stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $100.65, for a total value of $503,250.00. Following the transaction, the chief executive officer owned 2,262,500 shares in the company, valued at approximately $227,720,625. This trade represents a 0.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 55,000 shares of company stock valued at $5,287,900 over the last ninety days. Company insiders own 36.80% of the company’s stock.

Hedge Funds Weigh In On iRadimed

Several hedge funds and other institutional investors have recently modified their holdings of IRMD. Boothbay Fund Management LLC bought a new position in shares of iRadimed during the 3rd quarter worth approximately $279,000. Creative Planning acquired a new position in iRadimed during the third quarter worth about $315,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in iRadimed in the 3rd quarter worth about $395,000. Brevan Howard Capital Management LP acquired a new stake in shares of iRadimed in the second quarter valued at about $260,000. Finally, Prudential Financial Inc. bought a new stake in iRadimed in the second quarter worth approximately $240,000. Institutional investors own 92.34% of the company’s stock.

About iRadimed

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.